Q32 Bio (QTTB) Leerink Global Healthcare Conference 2025 summary

Strategic focus and program updates

• Clinical development is now centered on Bempikibart for alopecia areata, deprioritizing the Complement Program, which remains phase II ready for potential partnership or future development.

• Bempikibart targets IL-7 receptor alpha, blocking both IL-7 and TSLP, with broad potential in autoimmune and inflammatory diseases.

• The molecule demonstrates best-in-class pharmacology, with full receptor occupancy at low doses, minimal ADA, and a benign safety profile.

• Phase I and II data confirm robust pharmacokinetics, pharmacodynamics, and biomarker engagement consistent with clinical proof of concept.

• The company is opening an open-label extension and a new adaptive Part B trial to optimize dosing and duration for registrational studies.

Clinical trial results and efficacy insights

• Phase II Signal AD (atopic dermatitis) study showed strong biomarker and pharmacology data but was impacted by a high placebo response, with efficacy signals in the most severe patients.

• Phase II Signal AA (alopecia areata) study showed modest week 24 efficacy, similar to lower-dose JAK inhibitors, but uniquely maintained and deepened hair regrowth after treatment stopped, with effects persisting up to 55 weeks in some patients.

• 12 patients who regrew hair maintained it post-treatment, with 7 showing additional growth; a new open-label extension will formalize long-term data collection.

• Part B of the AA program will add a loading dose, treat for longer, and target 20 patients, with top-line data expected in the first half of next year.

• The remissive effect observed suggests a biologically distinct mechanism from JAK inhibitors, potentially positioning Bempikibart as a leading biologic in AA.

Pipeline expansion and future plans

• Bempikibart’s mechanism is applicable to other autoimmune diseases, with strong rationale for asthma, COPD, type 1 diabetes, MS, and ulcerative colitis.

• OSC’s positive ulcerative colitis data support the potential for Bempikibart, which may offer advantages in dosing and administration.

• The company is evaluating strategic options for the Complement Program, which showed strong pharmacology and safety but is not the current focus.

• Regulatory interactions indicate confidence in advancing to phase III, with safety and efficacy metrics aligned with FDA expectations for pivotal studies.

• The adaptive Part B trial is designed to inform optimal dosing regimens and support a registrational package for alopecia areata.